Invariant NKT cells increase drug-induced osteosarcoma cell death

Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials

(2011) J. S. Whelan et al.   ANNALS OF ONCOLOGY

Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells

(2011) Emilie P. Buddingh et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Harnessing natural killer T (NKT) cells in human myeloma: Progress and challenges

(2011) Madhav V. Dhodapkar et al.   CLINICAL IMMUNOLOGY

Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: Reversing tumor-induced defects

(2011) Mark A. Exley et al.   CLINICAL IMMUNOLOGY

PD-L2 is predominantly expressed by Th2 cells

(2011) W. Joost Lesterhuis et al.   MOLECULAR IMMUNOLOGY

Osteosarcoma

(2010) J. Ritter et al.   ANNALS OF ONCOLOGY

Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2010) P. C. W. Hogendoorn et al.   ANNALS OF ONCOLOGY

Expression of functional GPR35 in human iNKT cells

(2010) Silvia Fallarini et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Immune approaches to treating osteosarcoma

(2010) Nyessa Marina et al.   CANCER BIOLOGY & THERAPY

Cell Death Mechanisms Induced by Cytotoxic Lymphocytes

(2010) L Chávez-Galán et al.   Cellular & Molecular Immunology

Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans

(2010) Leonid S. Metelitsa   CLINICAL IMMUNOLOGY

Antigen-Specific Cytotoxicity by Invariant NKT Cells In Vivo Is CD95/CD178-Dependent and Is Correlated with Antigenic Potency

(2010) G. Wingender et al.   JOURNAL OF IMMUNOLOGY

Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects

(2010) Katherine A Janeway et al.   LANCET ONCOLOGY

Defective NKT Cell Activation by CD1d+ TRAMP Prostate Tumor Cells Is Corrected by Interleukin-12 with alpha-Galactosylceramide

(2010) Michael Nowak et al.   PLoS One

NKT cell costimulation: experimental progress and therapeutic promise

(2010) Marianne J. van den Heuvel et al.   TRENDS IN MOLECULAR MEDICINE

Clovamide and rosmarinic acid induce neuroprotective effects inin vitromodels of neuronal death

(2009) S Fallarini et al.   BRITISH JOURNAL OF PHARMACOLOGY

Osteosarcoma treatment: state of the art

(2009) Hang T. Ta et al.   CANCER AND METASTASIS REVIEWS

The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-γ production

(2009) Elvire Bourgeois et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Anti-inflammatory and vascularprotective properties of 8-prenylapigenin

(2009) Tiziana Paoletti et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasms

(2009) D. Bagnara et al.   HAEMATOLOGICA

The specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy

(2009) M. Taniguchi et al.   INTERNATIONAL IMMUNOLOGY

Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages

(2009) Liping Song et al.   JOURNAL OF CLINICAL INVESTIGATION

α-Galactosylceramide modulates the induction of indoleamine 2,3-dioxygenase in antigen presenting cells

(2008) Silvia Fallarini et al.   BIOCHEMICAL PHARMACOLOGY

Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide

(2008) Joanne E Croudace et al.   BMC IMMUNOLOGY

Invariant natural killer T cells and immunotherapy of cancer

(2008) Johan W. Molling et al.   CLINICAL IMMUNOLOGY

Modulation of invariant natural killer T cell cytokine responses by indoleamine 2,3-dioxygenase

(2008) Alberto Molano et al.   IMMUNOLOGY LETTERS

Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies

(2008) Shin-ichiro Fujii   TRENDS IN IMMUNOLOGY